Skip to main content
Erschienen in: Reviews in Endocrine and Metabolic Disorders 2/2018

12.03.2018

How should incidental NEN of the pancreas and gastrointestinal tract be followed?

verfasst von: Riccardo Ariotti, Stefano Partelli, Francesca Muffatti, Valentina Andreasi, Francesca Della Sala, Massimo Falconi

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Neuroendocrine gastro-entero-pancreatic neoplasms (GEP-NENs) constitute a heterogeneous group of tumors, whose incidence has increased over the years. The most frequent site for primary disease is the stomach followed by small and large intestine, and pancreas. In the last decade, a dramatic growing in the incidence of small, incidental GEP-NENs has been recorded. In parallel, an increasing attitude toward more conservative approaches instead of surgical management has being widely spreading. This is particularly true for small, asymptomatic, pancreatic NEN as for these tumor forms an active surveillance has proven to be safe and feasible. Primary site and biological features of the neoplasms lead to different strategies and indications for surveillance and follow-up. This review focuses on the current evidence on modality and timing of surveillance and conservative treatment of incidentally discovered lesions.
Literatur
1.
Zurück zum Zitat Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.CrossRef Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.CrossRef
2.
Zurück zum Zitat Vagefi PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg. 2007;142:347–54.CrossRef Vagefi PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg. 2007;142:347–54.CrossRef
3.
Zurück zum Zitat Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the Management of Patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103:153–71.CrossRef Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the Management of Patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103:153–71.CrossRef
4.
Zurück zum Zitat Delle Fave G, O'Toole D, Sundin A, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:119–24.CrossRef Delle Fave G, O'Toole D, Sundin A, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:119–24.CrossRef
5.
Zurück zum Zitat Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The north American neuroendocrine tumor society consensus guidelines for surveillance and medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017;46:707–14.CrossRef Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The north American neuroendocrine tumor society consensus guidelines for surveillance and medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017;46:707–14.CrossRef
6.
Zurück zum Zitat Fraenkel M, Kim M, Faggiano A, et al. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21:R153–63.CrossRef Fraenkel M, Kim M, Faggiano A, et al. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21:R153–63.CrossRef
7.
Zurück zum Zitat Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99:23–32.CrossRef Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99:23–32.CrossRef
8.
Zurück zum Zitat Campana D, Ravizza D, Ferolla P, et al. Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine. 2017;56:633–8.CrossRef Campana D, Ravizza D, Ferolla P, et al. Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine. 2017;56:633–8.CrossRef
9.
Zurück zum Zitat Rindi G, Azzoni C, La Rosa S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology. 1999;116:532–42.CrossRef Rindi G, Azzoni C, La Rosa S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology. 1999;116:532–42.CrossRef
10.
Zurück zum Zitat Marignani M, Delle Fave G, Mecarocci S, et al. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study. Am J Gastroenterol. 1999;94:766–72.PubMed Marignani M, Delle Fave G, Mecarocci S, et al. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study. Am J Gastroenterol. 1999;94:766–72.PubMed
11.
Zurück zum Zitat Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut. 1998;43:223–8.CrossRef Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut. 1998;43:223–8.CrossRef
12.
Zurück zum Zitat Campana D, Ravizza D, Ferolla P, et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine. 2016;51:131–9.CrossRef Campana D, Ravizza D, Ferolla P, et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine. 2016;51:131–9.CrossRef
13.
Zurück zum Zitat Ichikawa J, Tanabe S, Koizumi W, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy. 2003;35:203–6.CrossRef Ichikawa J, Tanabe S, Koizumi W, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy. 2003;35:203–6.CrossRef
14.
Zurück zum Zitat Uygun A, Kadayifci A, Polat Z, et al. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. J Surg Oncol. 2014;109:71–4.CrossRef Uygun A, Kadayifci A, Polat Z, et al. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. J Surg Oncol. 2014;109:71–4.CrossRef
15.
Zurück zum Zitat Merola E, Sbrozzi-Vanni A, Panzuto F, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012;95:207–13.CrossRef Merola E, Sbrozzi-Vanni A, Panzuto F, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012;95:207–13.CrossRef
16.
Zurück zum Zitat Ruszniewski P, Laucournet H, Elouaer-Blanc L, et al. Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy. Pancreas. 1988;3:145–52.CrossRef Ruszniewski P, Laucournet H, Elouaer-Blanc L, et al. Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy. Pancreas. 1988;3:145–52.CrossRef
17.
Zurück zum Zitat Tomassetti P, Migliori M, Caletti GC, et al. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med. 2000;343:551–4.CrossRef Tomassetti P, Migliori M, Caletti GC, et al. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med. 2000;343:551–4.CrossRef
18.
Zurück zum Zitat Fitzgerald TL, Dennis SO, Kachare SD, et al. Increasing incidence of duodenal neuroendocrine tumors: incidental discovery of indolent disease? Surgery. 2015;158:466–71.CrossRef Fitzgerald TL, Dennis SO, Kachare SD, et al. Increasing incidence of duodenal neuroendocrine tumors: incidental discovery of indolent disease? Surgery. 2015;158:466–71.CrossRef
19.
Zurück zum Zitat Margonis GA, Samaha M, Kim Y, et al. A multi-institutional analysis of duodenal neuroendocrine tumors: tumor biology rather than extent of resection dictates prognosis. J Gastrointest Surg. 2016;20:1098–105.CrossRef Margonis GA, Samaha M, Kim Y, et al. A multi-institutional analysis of duodenal neuroendocrine tumors: tumor biology rather than extent of resection dictates prognosis. J Gastrointest Surg. 2016;20:1098–105.CrossRef
20.
Zurück zum Zitat Zyromski NJ, Kendrick ML, Nagorney DM, et al. Duodenal carcinoid tumors: how aggressive should we be? J Gastrointest Surg. 2001;5:588–93.CrossRef Zyromski NJ, Kendrick ML, Nagorney DM, et al. Duodenal carcinoid tumors: how aggressive should we be? J Gastrointest Surg. 2001;5:588–93.CrossRef
21.
Zurück zum Zitat Dogeas E, Cameron JL, Wolfgang CL, et al. Duodenal and Ampullary carcinoid tumors: size predicts necessity for lymphadenectomy. J Gastrointest Surg. 2017;21:1262–9.CrossRef Dogeas E, Cameron JL, Wolfgang CL, et al. Duodenal and Ampullary carcinoid tumors: size predicts necessity for lymphadenectomy. J Gastrointest Surg. 2017;21:1262–9.CrossRef
22.
Zurück zum Zitat Woltering EA, Beyer DT, Thiagarajan R, Ramirez RA, Wang YZ, Ricks MJ. Boudreaux JP elevated plasma Pancreastatin, but not chromogranin a, predicts survival in neuroendocrine tumors of the duodenum. J Am Coll Surg. 2016;222(4):534–42.CrossRef Woltering EA, Beyer DT, Thiagarajan R, Ramirez RA, Wang YZ, Ricks MJ. Boudreaux JP elevated plasma Pancreastatin, but not chromogranin a, predicts survival in neuroendocrine tumors of the duodenum. J Am Coll Surg. 2016;222(4):534–42.CrossRef
23.
Zurück zum Zitat Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50:58–64.CrossRef Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50:58–64.CrossRef
24.
Zurück zum Zitat Cho M, Kim J, Sohn J, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000–2009: multicenter study. Cancer Res Treat. 2012;44:157–65.CrossRef Cho M, Kim J, Sohn J, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000–2009: multicenter study. Cancer Res Treat. 2012;44:157–65.CrossRef
25.
Zurück zum Zitat Scherubl H, Streller B, Stabenow R, et al. Clinically detected gastroenteropancreatic neuro- endocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol. 2013;19:9012–9.CrossRef Scherubl H, Streller B, Stabenow R, et al. Clinically detected gastroenteropancreatic neuro- endocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol. 2013;19:9012–9.CrossRef
26.
Zurück zum Zitat Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8–21.CrossRef Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8–21.CrossRef
28.
Zurück zum Zitat Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol. 2013;20:2815–21.CrossRef Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol. 2013;20:2815–21.CrossRef
29.
Zurück zum Zitat Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. 2011;150:75–82.CrossRef Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. 2011;150:75–82.CrossRef
30.
Zurück zum Zitat Lee LC, Grant CS, Salomao DR, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012;152:965–74.CrossRef Lee LC, Grant CS, Salomao DR, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012;152:965–74.CrossRef
32.
Zurück zum Zitat Partelli S, Cirocchi R, Crippa S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg. 2016;104:34–41.CrossRef Partelli S, Cirocchi R, Crippa S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg. 2016;104:34–41.CrossRef
33.
Zurück zum Zitat Sallinen V, Le Large TY, Galeev S, et al. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors - a systematic review and meta-analysis. HPB (Oxford). 2017;19:310–20.CrossRef Sallinen V, Le Large TY, Galeev S, et al. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors - a systematic review and meta-analysis. HPB (Oxford). 2017;19:310–20.CrossRef
34.
Zurück zum Zitat Ricci C, Casadei R, Taffurelli G, et al. Sporadic small (</=20 mm) nonfunctioning pancreatic neuroendocrine neoplasm: is the risk of malignancy negligible when adopting a more conservative strategy? A systematic review and meta-analysis. Ann Surg Oncol. 2017;24:2603–10.CrossRef Ricci C, Casadei R, Taffurelli G, et al. Sporadic small (</=20 mm) nonfunctioning pancreatic neuroendocrine neoplasm: is the risk of malignancy negligible when adopting a more conservative strategy? A systematic review and meta-analysis. Ann Surg Oncol. 2017;24:2603–10.CrossRef
35.
Zurück zum Zitat Triponez F, Goudet P, Dosseh D, et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30:654–62. discussion 663-654CrossRef Triponez F, Goudet P, Dosseh D, et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30:654–62. discussion 663-654CrossRef
36.
Zurück zum Zitat Partelli S, Tamburrino D, Lopez C, et al. Active surveillance versus surgery of nonfunctioning pancreatic neuroendocrine neoplasms </=2 cm in MEN1 patients. Neuroendocrinology. 2016;103:779–86.CrossRef Partelli S, Tamburrino D, Lopez C, et al. Active surveillance versus surgery of nonfunctioning pancreatic neuroendocrine neoplasms </=2 cm in MEN1 patients. Neuroendocrinology. 2016;103:779–86.CrossRef
37.
Zurück zum Zitat Melcescu E, Koch CA, Pancreatic neuroendocrine tumors. Clinical genomics: pratical applications in adult patient care, chapter 46 in Giovanni MA, Murray MF, Babyatsky M (eds). McGraw-Hill Medical, N Y. Melcescu E, Koch CA, Pancreatic neuroendocrine tumors. Clinical genomics: pratical applications in adult patient care, chapter 46 in Giovanni MA, Murray MF, Babyatsky M (eds). McGraw-Hill Medical, N Y.
38.
Zurück zum Zitat Yao J, Hassan M, Phan A, et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRef Yao J, Hassan M, Phan A, et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRef
39.
Zurück zum Zitat Boxberger N, Redlich A, Böger C, et al. Neuroendocrine tumors of the appendix in children and adolescents. Pediatr Blood Cancer. 2013;60:65–70.CrossRef Boxberger N, Redlich A, Böger C, et al. Neuroendocrine tumors of the appendix in children and adolescents. Pediatr Blood Cancer. 2013;60:65–70.CrossRef
40.
Zurück zum Zitat Mullen J, Savarese D. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol. 2011;104:41–4.CrossRef Mullen J, Savarese D. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol. 2011;104:41–4.CrossRef
41.
Zurück zum Zitat Emre A, Akbulut S, Bozdag Z, et al. Routine histopathologic examination of appendectomy specimens: retrospective analysis of 1255 patients. Int Surg. 2013;98:354–62.CrossRef Emre A, Akbulut S, Bozdag Z, et al. Routine histopathologic examination of appendectomy specimens: retrospective analysis of 1255 patients. Int Surg. 2013;98:354–62.CrossRef
42.
Zurück zum Zitat Henderson L, Fehily C, Folaranmi S, et al. Management and outcome of neuroendocrine tumours of the appendix-a two centre UK experience. J Pediatr Surg. 2014;49:1513–7.CrossRef Henderson L, Fehily C, Folaranmi S, et al. Management and outcome of neuroendocrine tumours of the appendix-a two centre UK experience. J Pediatr Surg. 2014;49:1513–7.CrossRef
43.
Zurück zum Zitat Amr B, Froghi F, Edmond M, et al. Management and outcomes of appendicular neuroendocrine tumours: retrospective review with 5-year follow-up. Eur J Surg Oncol. 2015;41:1243–6.CrossRef Amr B, Froghi F, Edmond M, et al. Management and outcomes of appendicular neuroendocrine tumours: retrospective review with 5-year follow-up. Eur J Surg Oncol. 2015;41:1243–6.CrossRef
44.
Zurück zum Zitat Quaedvlieg P, Visser O, Lamers C, et al. Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2,391 patients. Ann Oncol. 2001;12:1295–300.CrossRef Quaedvlieg P, Visser O, Lamers C, et al. Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2,391 patients. Ann Oncol. 2001;12:1295–300.CrossRef
45.
Zurück zum Zitat McGory M, Maggard M, Kang H, et al. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum. 2005;48:2264–71.CrossRef McGory M, Maggard M, Kang H, et al. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum. 2005;48:2264–71.CrossRef
46.
Zurück zum Zitat Landry C, Woodall C, Scoggins CR, et al. Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system. Arch Surg. 2008;143:664–70.CrossRef Landry C, Woodall C, Scoggins CR, et al. Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system. Arch Surg. 2008;143:664–70.CrossRef
47.
Zurück zum Zitat Wang A, Ahmad N. Rectal carcinoids. Curr Opin Gastroenterol. 2006;22:529–35.CrossRef Wang A, Ahmad N. Rectal carcinoids. Curr Opin Gastroenterol. 2006;22:529–35.CrossRef
48.
Zurück zum Zitat Ramage J, De Herder W, Delle Fave G, et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:139–43.CrossRef Ramage J, De Herder W, Delle Fave G, et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:139–43.CrossRef
49.
Zurück zum Zitat Anthony L, Strosberg J, Klimstra D, et al. The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs). Well-Differentiated NETs of the Distal Colon and Rectum. Pancreas. 39:767–74.CrossRef Anthony L, Strosberg J, Klimstra D, et al. The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs). Well-Differentiated NETs of the Distal Colon and Rectum. Pancreas. 39:767–74.CrossRef
50.
Zurück zum Zitat Kobayashi K, Katsumata T, Yoshizawa S, et al. Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography. Dis Colon Rectum. 2005;48:285–91.CrossRef Kobayashi K, Katsumata T, Yoshizawa S, et al. Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography. Dis Colon Rectum. 2005;48:285–91.CrossRef
51.
Zurück zum Zitat Berkelhammer C, Jasper I, Kirvaitis E, et al. “Band-snare” resection of small rectal carcinoid tumors. Gastrointest Endosc. 1999;50:582–5.CrossRef Berkelhammer C, Jasper I, Kirvaitis E, et al. “Band-snare” resection of small rectal carcinoid tumors. Gastrointest Endosc. 1999;50:582–5.CrossRef
52.
Zurück zum Zitat Ono A, Fujii T, Saito Y, et al. Endoscopic submucosal resection of rectal carcinoid tumors with a ligation device. Gastrointest Endosc. 2003;57:583–7.CrossRef Ono A, Fujii T, Saito Y, et al. Endoscopic submucosal resection of rectal carcinoid tumors with a ligation device. Gastrointest Endosc. 2003;57:583–7.CrossRef
53.
Zurück zum Zitat Okamoto Y, Fujii M, Tateiwa S, et al. Treatment of multiple rectal carcinoids by endoscopic mucosal resection using a device for esophageal variceal ligation. Endoscopy. 2004;36:469–70.CrossRef Okamoto Y, Fujii M, Tateiwa S, et al. Treatment of multiple rectal carcinoids by endoscopic mucosal resection using a device for esophageal variceal ligation. Endoscopy. 2004;36:469–70.CrossRef
54.
Zurück zum Zitat Imada-Shirakata Y, Sakai M, Kajiyama T, et al. Endoscopic resection of rectal carcinoid tumors using aspiration lumpectomy. Endoscopy. 1997;29:34–8.CrossRef Imada-Shirakata Y, Sakai M, Kajiyama T, et al. Endoscopic resection of rectal carcinoid tumors using aspiration lumpectomy. Endoscopy. 1997;29:34–8.CrossRef
55.
Zurück zum Zitat Niederle B, Pape UF, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103:125–38.CrossRef Niederle B, Pape UF, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103:125–38.CrossRef
56.
Zurück zum Zitat Hughes MS, Azoury SC, Assadipour Y, et al. Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs). Surgery. 2016;159:350–6.CrossRef Hughes MS, Azoury SC, Assadipour Y, et al. Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs). Surgery. 2016;159:350–6.CrossRef
57.
Zurück zum Zitat Lardiere-Deguelte S, de Mestier L, Appere F, et al. Toward a preoperative classification of lymph node metastases in patients with small intestinal neuroendocrine tumors in the era of intestinal-sparing surgery. Neuroendocrinology. 2016;103:552–9.CrossRef Lardiere-Deguelte S, de Mestier L, Appere F, et al. Toward a preoperative classification of lymph node metastases in patients with small intestinal neuroendocrine tumors in the era of intestinal-sparing surgery. Neuroendocrinology. 2016;103:552–9.CrossRef
Metadaten
Titel
How should incidental NEN of the pancreas and gastrointestinal tract be followed?
verfasst von
Riccardo Ariotti
Stefano Partelli
Francesca Muffatti
Valentina Andreasi
Francesca Della Sala
Massimo Falconi
Publikationsdatum
12.03.2018
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 2/2018
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-018-9445-4

Weitere Artikel der Ausgabe 2/2018

Reviews in Endocrine and Metabolic Disorders 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.